Esperion Therapeutics (ESPR) Accumulated Expenses (2012 - 2026)

Esperion Therapeutics' Accumulated Expenses history runs 15 years deep, the most recent figure standing at $17.5 million for Q1 2026.

• Quarterly Accumulated Expenses rose 5.2% year-over-year to $17.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.5 million (up 5.2% YoY) and the FY2025 annual result came in at $19.2 million, up 51.1% from the prior year.
• Accumulated Expenses was $17.5 million for Q1 2026 at Esperion Therapeutics, down from $19.2 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $30.2 million in Q1 2022 and bottomed at $1.6 million in Q3 2025.
• A 5-year average of $13.6 million and a median of $12.7 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2023 — Accumulated Expenses surged 360.71% — and 2025, when it tumbled 85.47%.
• Esperion Therapeutics' Accumulated Expenses stood at $5.4 million in 2022, then jumped by 360.71% to $25.0 million in 2023, then plunged by 49.04% to $12.7 million in 2024, then soared by 51.1% to $19.2 million in 2025, then declined by 9.14% to $17.5 million in 2026.
• Business Quant data shows ESPR's Accumulated Expenses at $17.5 million in Q1 2026, $19.2 million in Q4 2025, and $1.6 million in Q3 2025.